Tolerability of eslicarbazepine acetate as adjunctive therapy of adult patients with partial-onset seizures up to one year of follow-up

2013 ◽  
Vol 333 ◽  
pp. e43-e44
Author(s):  
C. Elger ◽  
E. Ben-Menachem ◽  
A. Gil-Nagel ◽  
R. Sousa ◽  
H. Gama ◽  
...  
Keyword(s):  
Adjunctive Therapy ◽  
Adult Patients ◽  
Eslicarbazepine Acetate ◽  
One Year

Efficacy of eslicarbazepine acetate as adjunctive therapy of adult patients with partial-onset seizures up to one year of follow-up

2013 ◽  
Vol 333 ◽  
pp. e43 ◽  
Author(s):  
A. Gil-Nagel ◽  
C. Elger ◽  
E. Ben-Menachem ◽  
R. Sousa ◽  
J. Moreira ◽  
...  
Keyword(s):  
Adjunctive Therapy ◽  
Adult Patients ◽  
Eslicarbazepine Acetate ◽  
One Year

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy

2010 ◽  
Vol 89 (2-3) ◽  
pp. 278-285 ◽  
Author(s):  
E. Ben-Menachem ◽  
A.A. Gabbai ◽  
A. Hufnagel ◽  
J. Maia ◽  
L. Almeida ◽  
...  
Keyword(s):  
Adjunctive Therapy ◽  
Partial Epilepsy ◽  
Adult Patients ◽  
Eslicarbazepine Acetate

TREATMENT OF TRIGGER FINGERS BY INJECTION OF METHYLPREDNISOLONE ACETATE AND LIDOCAINE (DEPO-MEDROL®)

Hand Surgery ◽  
1996 ◽  
Vol 01 (02) ◽  
pp. 103-105
Author(s):  
J. Joris Hage ◽  
Jaap D.K. Munting
Keyword(s):  
Side Effects ◽  
Prospective Study ◽  
Success Rate ◽  
Adult Patients ◽  
Methylprednisolone Acetate ◽  
Short Term ◽  
Local Injections ◽  
One Year ◽  
A Prospective Study

Thirty-six adult patients with 44 trigger fingers of less than four months' duration entered a prospective study on the efficiency of treatment with local injections of a combination of corticosteroids and lidocaine. From this study it may be concluded that the short-term success rate (93%) of one to three injections of methylprednisolone and lidocaine 2% (Depo-Medrol®) is comparable to that achieved by surgical or percutaneous tenolysis. At one year of follow-up, this success rate still amounted to 86%. In our hands, this therapy is without complications or side effects.

scholarly journals The treatment of coccydynia in adolescents

2020 ◽  
Vol 1 (5) ◽  
pp. 115-120
Author(s):  
Ante Matti Kalstad ◽  
Rainer Günter Knobloch ◽  
Vilhjalmur Finsen
Keyword(s):  
Pain Scale ◽  
Adult Patients ◽  
Injection Therapy ◽  
Control Group ◽  
Treatment Results ◽  
Results Of Treatment ◽  
Adolescent Patients ◽  
Numeric Pain Scale ◽  
One Year

Aims To determine if the results of treatment of adolescents with coccydynia are similar to those found in adults. Adult patients with coccydynia may benefit from injection therapy or operative treatment. There is little data evaluating treatment results in adolescents. We have treated adolescent patients similarly to adults and compared the outcomes. Methods Overall, 32 adolescents with coccydynia were treated at our institution during a seven-year period; 28 responded to final follow-up questionnaires after a minimum of one year, 14 had been treated with only injection therapy, and 14 had been operated with coccygectomy. We collected data with regards to pain while sitting, leaning forward, rising from a sitting position, during defecation, while walking or jogging, and while travelling in trains, planes, or automobiles. Pain at follow-up was registered on a numeric pain scale. Each adolescent was then matched to adult patients, and results compared in a case control fashion. The treatment was considered successful if respondents were either completely well or much better at final follow-up after one to seven years. Results Out of the 28 treated adolescents, 14 were regarded as successfully treated. Seven were somewhat better, and the remaining seven were unchanged. In the adult control group the corresponding number was 15 successfully treated, eight patients were somewhat better, and five were unchanged. Six of the 14 successfully treated adolescents had been operated. There were no significant differences between the groups in the various registered domains, or on numeric pain scale. Conclusion Treatment results in adolescent patients seem similar to those in adults. The long-term success rate of injection therapy is low. In case of injection treatment failure, operation may be considered, also in adolescents.

Re-Induction Chemotherapy Using FLAG-Mitoxantrone for Adult Patients with Relapsed Acute Leukemia: A Single Center Experience From United Arab Emirates

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4339-4339
Author(s):  
Inaam Bashir Hassan ◽  
Arif Alam ◽  
Hussain Sabir ◽  
Amar Lal ◽  
Khalid Al qawasmeh ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Median Time ◽  
United Arab Emirates ◽  
Conflicts Of Interest ◽  
Adult Patients ◽  
Term Survival ◽  
Overall Response ◽  
One Year ◽  
Time To Relapse

Abstract Abstract 4339 In a descriptive retrospective study, we evaluated the outcome of 47 adult patients with relapsed acute leukemia (AL) (AML= 26 and ALL = 21) diagnosed between 2000 and 2009 at our center. All patients received re-induction according to a FLAG-mitoxantrone regimen consisting of cytarabine 2g/m2 over 2 hours (day 1–5), fludarabine 30mg/m2 over 30 minutes (day 1–5), mitoxantrone 10 mg/m2 over 1 hour (day 1, 3 & 5) and G-CSF 300 micg sc daily from day 6 until neutrophil count ≥ 1.0 ×109. The median age at relapse was 32 years (17 – 65) for all patients, 38.2 years (7.8 – 65.1) for AML and 23.8 years (17.3 – 58.6) for ALL. Median time to relapse was 11 months (2 – 49) for all patients, 10.5 months (2 –28) for AML and 14 months (4 – 43) for ALL. For assessment of response to re-induction two patients were excluded from the analysis as their response status could not be documented (both left the United Arab Emirates early). The overall response rate was 62.1% (28/45 patients). Of these 25 (55.6%) patients achieve complete remission (CR) and 3 AML patients (6.7%) had a partial response (PR). CR were significantly superior when time to relapse > one year (P=0.036) compared to < one year (71.4% versus 41.7%) and for ALL compared to AML patients (63.2% versus 50.0%; p=0.026). Patient younger than 35 years of age at diagnosis and at relapse achieved CR more frequently than older patients (64.3% versus 41.2%), however the differences were not statistically significant (p=0.32). WBC at diagnosis <100×109/l was a significant predictor (p=0.05) for the overall response (73.5% for WBC <100×109/l versus 37.5% for WBC >100×109/l). Median time to recovery of neutrophils (≥1.0×109/l) among all patients with response was 25 days (19–33), 24 days (19–25) for ALL patients and 26 days (23–37) for AML patients. Thirty eight patients had documented neutropenic fever requiring prolonged antibiotic therapy where 7 of them had systemic antifungal therapy due to classical finding on CT or documented invasive asparagillus infection. Early death occurred in 6 patients (12.8%) which was significantly higher in patient with ALL compared to AML (23.8% versus 3.8%; p=0.041) mainly due to infections and secondary multi-organ failure. Median follow up from relapse was 3.0 months (1–120) for all patients, 3.5 months (1–120) for AML, 2 months (1–118) for ALL and 11 month (1–120) for patients in CR. Seven of the 25 patients in CR had consolidation with chemotherapy only (a second course of FLAG-mitoxantrone) followed by maintenance therapy in one patient with ALL. Eight patients underwent allogeneic stem cell transplantation (allo-SCT) abroad with post transplantation follow up at our center in addition to other 7 patient who left with a plan for allo-SCT without any further follow up at our center due to lack of feedback from the transplant center. At last follow up 18 patients were alive in CR2, 19 dead and 10 had refractory or relapsed disease. Overall survival (OS) from relapse at 12 and 18 month were 47.7% and 33.4%. Achievement of CR after re-induction (60.0% for CR versus 0.00% for no CR) and any type of consolidation therapy including a second course of FLAG-mitoxantrone or allo-SCT (59.8% for consolidation versus 12.2% for no consolidation) were significant predictor for superior OS among all patients (p=0.008 and p=0.001 respectively) while WBC <5×109/l at relapse was a significant predictor for inferior OS (26.7% versus 83.3%; p=0.04) among CR patients only. Currently 23 were lost for follow up since they left the UAE and only 5 patients are alive in CR2 (4 post allo-SCT and one post maintenance chemotherapy) with a median follow up of 71 months (18–120). In our experience FLAG-mitoxantrone is an effective regimen for induction of a second CR in relapsed AL with acceptable toxicity, however, allo-SCT is essential for long term survival. Disclosures: No relevant conflicts of interest to declare.

Experience with Eslicarbazepine Acetate Treatment at a Pediatric Epilepsy Center

2020 ◽  
Author(s):  
Ahmet Tanritanir ◽  
Xiaofan Wang ◽  
Tobias Loddenkemper
Keyword(s):  
Sleep Problems ◽  
Retention Rate ◽  
Intractable Epilepsy ◽  
Pediatric Epilepsy ◽  
Seizure Freedom ◽  
Eslicarbazepine Acetate ◽  
Once Daily ◽  
Epilepsy Center ◽  
One Year

AbstractEslicarbazepine acetate (ESL) is a novel, once-daily antiseizure medication. We evaluated the efficacy and safety profile of ESL treatment in epilepsy patients at a single tertiary epilepsy center. In this retrospective observational study, we included 32 patients with pharmacologically intractable epilepsy receiving ESL at Boston Children's Hospital from June 2014 to June 2018. We assessed treatment outcome in terms of efficacy and tolerability at first and last follow-up (f/u). Median age was 17 (interquartile range: 10.8–20.7; range: 6.5–36) years. Twelve (37.5%) patients, including three with seizure freedom, were responders at last f/u. Eleven patients discontinued ESL due to seizure worsening (9, 28%), adverse events (AEs) (2, 6%) or both (4, 12%). Responders showed greater seizure reduction at last f/u with fewer AEs as compared with nonresponders. Ten (31%) patients developed AEs, the most common being sleep problems (5, 15%). One-year retention rate with ESL treatment was 54%. In conclusion, ESL had a good response rate in patients with pharmacologically intractable epilepsy, with about one-third of patients developing AEs.

Sign in / Sign up

Export Citation Format

Share Document